Abe is a Vice President at Samsara BioCapital, a Life Sciences fund focused on investing in and building long-term relationships with entrepreneurs and management teams advancing novel medicines. The fund manages approximately $410M in assets. Before joining Samsara, Abe was Director of Program Biology at Revolution Medicines, where he co-led some of the company’s preclinical oncology and infectious disease programs. Abe was also Director of Program Development at bluebird bio, where he worked on the company’s genetic disease programs focused on hemoglobin disorders and neurodegeneration. Before that, as an Associate at Third Rock Ventures, he was involved in the creation of Blueprint Medicines.
This panel will discuss the status quo on VC investment in Cardiovascular Disease. Panelists will explore how new preclinical discovery paradigms, the use of personalized medicine approaches (i.e. biomarkers for patient stratification and trial acceleration) and novel therapeutic modalities could change the trajectory of VC investment in the Cardiovascular Space.